Press Releases

BOSTON and SYDNEY — 18 March 2019 — GI Dynamics® Inc. (ASX:GID) (Company or GI Dynamics), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has agreed to the terms of a US $1,000,000 convertible note and warrant...

BOSTON and SYDNEY — 15 March 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive results on final data from the United Kingdom’s National Health Service (NHS) EndoBarrier...

BOSTON and SYDNEY — 14 February 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has received Institutional Review Board (IRB) approval to conduct its pivotal trial of...

BOSTON and SYDNEY — 4 January 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the appointment of Stephen Linhares to the position of vice president of clinical and regulatory affairs....

BOSTON and SYDNEY – 2 January 2019 – GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has reached an agreement with Crystal Amber Fund Limited (Crystal Amber) to extend the maturity...

BOSTON and SYDNEY — 11 December 2018 — GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to announce the appointment of Charles Carter to the position of chief financial officer. Carter’s role with GI Dynamics will encompass finance, accounting and...

Trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity. BOSTON, SYDNEY, HYDERABAD, India — 28 November 2018 — GI Dynamics Inc. (ASX: GID), a medical device company that is developing EndoBarrier for patients diagnosed with type 2 diabetes and obesity,...

BOSTON and SYDNEY — 16 November 2018 — GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to announce that,  following stockholder approval obtained on 30 October 2018 at the Company’s Special Meeting, it has successfully completed the issue of the...

BOSTON and SYDNEY — 1 November 2018 — GI Dynamics, Inc. (ASX:GID), a medical device company that is developing EndoBarrier, held a Special Meeting on Monday, 29 October 2018 at 5:00pm United States Eastern Daylight Time (being Tuesday, 30 October 2018 at 8:00am Australian Eastern Daylight Time)...

BOSTON and SYDNEY — 16 October 2018 — GI Dynamics, Inc. (ASX:GID), a medical device company that is developing EndoBarrier for patients with type 2 diabetes and obesity, is pleased to confirm, further to its announcement released on 21 September 2018, the attached proxy statement and notice of a...